ReviewACS omega2026
Next-Generation Bioinks in 3D Bioprinting: Advances, Challenges, and Emerging Opportunities.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting is an innovative technology that has advanced the field of tissue engineering and regenerative medicine by allowing the layer-by-layer deposition of cells, biomaterials, and bioactive molecules to create sophisticated biological constructs. In this context, bioinks serve as essential vehicles for creating a microenvironment that can support cell attachment, proliferation, differentiation, and maturation into tissues and organs. The current review offers a complete review of the key aspects associated with the development of 3D bioprinting bioinks, including design concepts, classification, properties, and latest trends. Several important characteristics and features of bioinks, namely, rheology, cross-linking mechanism, cell-matrix interactions, degradation process, and biofunctionalization approach, are analyzed in detail. Natural, synthetic, and hybrid bioinks with regard to printability, biocompatibility, mechanical strength, and potential for tissue regeneration are comparatively discussed. Major technologies used for bioprinting, such as inkjet printing, extrusion printing, and laser-assisted printing, are presented. Moreover, recent advances in multimaterial printing, coaxial printing, vascularization, and maturation processes in 3D bioprinting are considered. Next-generation bioinks such as nanocomposite bioinks, decellularized extracellular matrix-based bioinks, stimuli-responsive smart bioinks, 4D bioprinting materials, and artificially designed bioinks are discussed. Applications of bioprinting in skin, bone, cartilage, neural, cardiac, and tumor tissue engineering, drug screening, and personalized medicine are emphasized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.